Skip to main content
. Author manuscript; available in PMC: 2016 Sep 8.
Published in final edited form as: J Am Coll Cardiol. 2015 Sep 8;66(10):1119–1128. doi: 10.1016/j.jacc.2015.06.1332

Figure 1. Survival in Patients with Lung and Breast Cancer.

Figure 1

While the presence of malignant cells in PE in lung cancer patients (A) led to significantly worse survival than for those without (median overall survival: 51 [95% CI: 29 to 99] vs. 287 days [95% CI: 55 to not estimable]), there was no significant survival difference in patients with breast cancer (B) (317 [95% CI: 71 to not estimable] vs. 241 days [95% CI: 46 to 376]).